Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CanROC Epinephrine Dose: Optimal Versus Standard Evaluation Trial (CanROC EpiDOSE Trial)

NCT03826524 is registered in ClinicalTrials.gov with Unity Health Toronto as lead sponsor.

NCT NCT03826524
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03826524 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CanROC Epinephrine Dose: Optimal Versus Standard Evaluation Trial (CanROC EpiDOSE Trial)
Lead sponsor
Unity Health Toronto
Phase
Phase 4
Overall status
Recruiting
Start date
May 24, 2023
Completion date
December 31, 2028
Enrollment
1,250 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

cardiac arrest, out-of-hospital, sudden cardiac arrest, ventricular fibrillation, ventricular tachycardia-pulseless